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Background: Expression of NRIF3 (Nuclear Receptor Interacting Factor-3) rapidly and selectively leads to apoptosis
of breast cancer cells. This occurs through binding of NRIF3 or its 30 amino acid Death Domain-1 (DD1) region to
the transcriptional repressor, DIF-1 (DD1 Interacting Factor-1). DIF-1 acts in a wide variety of breast cancer cells but
not other cell types to repress the pro-apoptotic gene, FASTKD2. Expression of NRIF3 or DD1 inactivates the DIF-1
repressor leading to rapid derepression of FASTKD2, which initiates apoptosis within 5–8 h of expression. Although
FASTKD2 is an inner mitochondrial membrane protein, it does not require mitochondrial localization to initiate apoptosis.
Methods: Androgen dependent LNCaP cells as well as two androgen independent LNCaP cell lines (LNCaP-AI and
LNCaP-abl) were studied and LNCaP-AI cells were engineered to conditionally express DD1 or the inactive
DD1-S28A with 4-hydroxytamoxifen. Apoptosis was assessed by TUNEL assay. FASTKD2 is related to 4 other proteins
encoded in the human genome (FASTKD1, 3, 4, 5). All contain a poorly conserved putative bipartite kinase domain
designated as FAST1_FAST2. We examined whether expression of any of the other FASTKD isoforms leads to apoptosis
and sought to identify the region of FASTKD2 necessary to initiate the apoptotic pathway.
Results: Of the FASTKD1-5 isoforms only expression of FASTKD2 leads to apoptosis. Although, the NRIF3/DD1/DIF-1
pathway does not mediate apoptosis of a wide variety of non-breast cancer cell lines, because of certain similarities and
gene signatures between breast and prostate cancer we explored whether the NRIF3/DD1/DIF-1/FASTKD2 pathway
mediates apoptosis of prostate cancer cells. We found that the pathway leads to apoptosis in LNCaP cells, including
the two androgen-independent LNCaP cell lines that are generally resistant to apoptosis. Lastly, we identified that
FASTKD2-mediated apoptosis is initiated by the 81 amino acid FAST2 region.
Conclusions: The NRIF3/DIF-1/FASTKD2 pathway acts as a “death switch” in breast and prostate cancer cells. Deciphering
how this pathway is regulated and how FASTKD2 initiates the apoptotic response will allow for the development of
therapeutic agents for the treatment of androgen-independent prostate cancer or Tamoxifen-unresponsive Estrogen
Receptor negative tumors as well as metastatic breast or prostate cancer.
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Programmed cell death or apoptosis, a fundamental
process in growth and development, can be targeted in
the treatment of various tumors [1]. Several years ago
we identified a nuclear hormone receptor co-activator
which we refer to as Nuclear Receptor Interacting
Factor 3 (NRIF3) [2]. Surprisingly we found that ex-
pression of NRIF3 rapidly leads to caspase-2-dependent
apoptosis in a wide variety of Estrogen Receptor posi-
tive or negative human breast cancer cell lines (e.g.
SKBR3, MCF-7, T-47D, MDA-435, MDA-231 and
MDA-231/ER+) and two mouse breast cancer cell lines
(4T1 and 67NR) [2-5]. However, NRIF3 expression did
not lead to apoptosis in a wide variety of other cell types
(e.g. U2OS, human osteosarcoma; 293, human kidney epi-
thelium; UOK-145, kidney carcinoma; HepG2, human
hepatoma, and HeLa, human cervical carcinoma) [2-4].
Apoptosis mediated by NRIF3 was documented by FACS
analysis, binding of Annexin V, time-lapse imaging, and
TUNEL assay [2,3]. This apoptotic activity was mapped to
a short ~30 amino acid region (amino acids 20–50) of
NRIF3. We refer to this region as Death Domain-1 (DD1)
since it is necessary and sufficient to mediate apoptosis of
breast cancer cells. DD1 does not interact with nuclear
receptors, thus, this apoptotic effect of NRIF3 is inde-
pendent of its action as a nuclear receptor co-activator.
Change of Ser28 to Ala28 (S28A) abrogates the ability
of NRIF3/DD1 to mediate apoptosis suggesting that
phosphorylation of Ser28 is important for this bio-
logical effect of NRIF3/DD1 [2,3].
We cloned the intracellular target of NRIF3/DD1 and
refer to this factor as DD1 Interacting Factor-1 (DIF-1)
which is a transcriptional repressor [4]. Our studies indi-
cated that DIF-1 (a.k.a IRF-2BP2) acts to selectively repress
one or more pro-apoptotic genes in breast cancer cells (but
not in the other cell types examined) and this repression is
reversed by the binding of NRIF3/DD1 [4]. The notion that
DIF-1 represses pro-apoptotic genes in breast cancer cells
is further supported by the finding that knockdown of DIF-
1 by siRNA leads to apoptosis of breast cancer cells but not
of other cell types; including MCF-10A cells and C57MG
cells, which are respectively immortalized normal human
and mouse breast epithelial cell lines [4]. Thus, DIF-1 acts
as a “death switch” whose activity can be attenuated by the
binding of NRIF3/DD1 leading to pro-apoptotic gene
expression in breast cancer cells [4].
Through microarray and expression studies, we identi-
fied FASTKD2 (Fas Activated Serine-Threonine Kinase
Domains 2) as the pro-apoptotic target gene that is re-
pressed by DIF-1 in breast cancer cells but not other cell
types [5]. DIF-1 binds to the FASTKD2 gene in breast
cancer cells but not to the FASTKD2 gene in other cell
types (e.g. HeLa cells) [5]. Knockdown of FASTKD2 by
siRNA prevents NRIF3/DD1-mediated apoptosis in breastcancer cells while expression of FASTKD2 leads to apop-
tosis in all cell types [5]. Our findings are consistent with a
model where rapid and transient de-repression of the
FASTKD2 gene in breast cancer cells leads to apoptosis [5].
Although, the NRIF3/DD1/DIF-1 pathway does not me-
diate apoptosis of a wide variety of non-breast cancer cell
lines, because of certain similarities and gene signatures
between breast and prostate cancer [6-8] we explored
whether the NRIF3/DD1/FASTKD2 pathway mediates
apoptosis of prostate cancer cell lines. We examined
LNCaP cells which are androgen dependent (LNCaP-
AD) [9] as well as two other LNCaP cell lines which
express high levels of androgen receptor but are andro-
gen independent with regard to growth (LNCaP-AI and
LNCaP-abl) [10,11]. Interestingly, LNCaP-AI and LNCaP-
abl are much more resistant to apoptosis than androgen
dependent LNCaP-AD cells [10,11]. Here we report that
all three LNCaP cell lines rapidly undergo apoptosis in
response to NRIF3/DD1 through the rapid expression of
the FASTKD2 gene. Moreover, we document that an 81
amino acid sequence in the putative FASTKD2 kinase
domain region is sufficient to mediate apoptosis in LNCaP
cells and other cell types.
Methods
Plasmids
pLPC-DD1-ERT2 or pLPC-DD1(S28A)-ERT2 retroviral
based plasmids were described previously [5] and the
expressed proteins are activated by by 4-hydroxytamoxifen
(4-OHT). These vectors express a chimera with an
N-Terminal FLAG epitope and a nuclear localization signal
[5]. Full-length FASTKD2 generated by PCR and cloned
into p3xFLAG-CMV-14 (Sigma) to yield FASTKD2 with a
C-terminal 3xFLAG tag was described previously [5].
FASTKD2 lacking both the FAST kinase and the RAP
domains [FASTKD2(1–455)] was generated by PCR and
cloned into the EcoRI-KpnI site of p3xFLAG-CMV-14.
DNA corresponding to the FAST2 domain (amino acids
538–619) and the FAST1_FAST2 region (amino acids
456–619) were generated by PCR and cloned into the
EcoR1-KpnI site of pEGFP-C3. The number designations
used are as described by Simarro et al. [12] although it has
been suggested that Met 17 is the initiating codon [13]. All
constructs were confirmed by sequencing. Vectors ex-
pressing pEGFP-DD1 and GAL4-DD1 and GAL4-DD1
(S28A) and AIF-GFP were described previously [2]. YFP
vectors expressing all five FASTKD proteins [12] were
generously provided by Maria Simarro and Paul Anderson.
Stable cell lines
LNCaP-AI cell lines stably expressing a DD1-ERT2 or a
DD1(S28A)-ERT2 chimera were generated as previously
described for T-47D, MCF-7 and SKBR3 breast cancer
cells and HeLa cells [5]. In summary, 293T cells, seeded in
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with ψA retroviral packaging vector and either pLPC-
DD1-ERT2 or pLPC-DD1(S28A)-ERT2 by calcium phos-
phate precipitation. The retroviral supernatant was
collected at 36 h and 60 h post-transfection. The super-
natant was then filtered through a 0.45 um sterile filter
and added to LNCaP-AI cells for infection. Forty-eight h
post-infection, cells were selected through resistance to 2
ug/ml puromycin for two weeks. Single colonies of each
of the stable cell lines were isolated by serial dilution and
screened for the expression of DD1-ERT2 or DD1(S28A)-
ERT2 by immunofluorescence using FLAG-M2 antibody
(Sigma). Expression of DD1-ERT2, or DD1(S28A)-ERT2
in the isolated clones was also confirmed by FLAG-M2
Western blotting.
Cell culture
All cell lines except HeLa were maintained in Dulbec-
co's modified Eagle's medium (DMEM) containing 10%
fetal bovine serum (FBS) supplemented with glutamine
and antibiotics. HeLa cells were maintained in DMEM
containing 10% bovine calf serum supplemented with
glutamine and antibiotics. Stable cell lines were maintained
in DMEM-10% serum supplemented with glutamine and 2
ug/ml puromycin.
siRNA transfection
siRNAs to knockdown FASTKD2 expression were ob-
tained from Qiagen and were previously verified to knock-
down FASTKD2 by over 90% [5]. The target sequence for
FASTKD2 was ATGAATCACCGATCTCTTATA. A con-
trol siRNA contained four base changes. Cells were trans-
fected with the siRNAs (40 nM) using HiPerfect siRNA
transfection reagent (Qiagen) according to manufactur-
er's recommendation. To obtain efficient knockdown in
LNCaP-AI cells, the cells were transfected with the
siRNAs twice (on day 1 and day 2) and the cells were
studied ~70 h after the initial tranfection.
TUNEL assay
Cell lines were plated at a density of 30,000 cells per well
on glass coverslips in 48-well tissue culture plates [4].
About 24 h later, the cells were transfected with the
siRNA(s) as indicated using HiPerfect (Qiagen) or the
indicated plasmids (50 ng) using Lipofectamine 2000
(Invitrogen). Generally, cells were usually harvested 15 h
after plasmid transfection. The DD1-ERT2 and DD1
(S28A)-ERT2 stable cell lines were examined between 5 to
15 h after the addition of 1 uM 4-OHT as indicated. Cells
were washed three times with phosphate-buffered saline,
fixed in 4% formaldehyde, and assayed for TUNEL using
the in situ Cell Death Detection TMR red kit (Roche Diag-
nostics). Cells were then stained with 4',6-diamidino-2-
phenylindole (DAPI) to visualize nuclei, mounted onslides, examined by fluorescent microscopy, and digitally
photographed. Magnification bars are shown at the lower
right of each TUNEL assay figure.
Quantitative reverse transcription PCR (qRT-PCR)
qRT-PCR was carried out using total RNA extracted from
cells using TRIzol (Invitrogen). One ug of RNA was treated
with DNase1 (Fermentas), and reverse transcribed with
random hexamers using a cDNA kit (Applied Biosystems)
according to manufacturer's protocol. Specific PCR prod-
ucts were amplified using the FASTKD2 PCR primers [5]
(forward primer, TCCTGAATCCCTAAACATGAAAA;
reverse primer, GCCATAACTTCCACGAACTG), a 1:50
dilution of cDNA, and the Maxima SYBR Green/Fluores-
cein qPCR Master Mix (Fermentas). Forward and reverse
primers for qRT-PCR of the other 4 FASTKD mRNAs
(FASTKD1,3,4,5,) were as previously described [12]. SYBR
green signals were measured in a BioRad iCycler machine.
The values were normalized to an internal 18S ribosomal
RNA control.
Immunofluorescence
Cells were plated, treated, and fixed as described in the ex-
periments for TUNEL assay. FLAG-M2 antibody (Sigma)
and anti-mouse FITC antibody (Zymed) were used to stain
for FLAG-DD1-ERT2 or FASTKD2-FLAG expression in
fixed cells. After treatments and/or transfections, cells were
fixed, and permeabilized with 1x PBS with 0.2% Triton-
X100 for 10 min at 25°C. After 3 washes of 1x PBS, the
cells were blocked with 3% BSA in 1x PBS for 45 min at
25°C, then incubated with 3 ug/ml of FLAG-M2 antibody
(Sigma) in 3% BSA in 1x PBS. After the primary antibody
incubation, the cells were washed three times in 1x PBS.
The cells were then incubated with 7.5 ug/ml of the
secondary anti-mouse FITC antibody (Zymed) for 1 h at
25°C. The cells were finally washed three times in 1x PBS,
and stained with DAPI to visualize nuclei, mounted on
slides, examined by fluorescent microscopy, and digitally
imaged. Magnification bars are shown at the lower right
of each figure.
Results
NRIF3/DD1 expression mediates apoptosis of LNCaP cells
through activation of caspase-2 and an increase in
mitochondrial permeability
In previous studies apoptosis mediated by NRIF3 in breast
cancer cells was documented by FACS analysis, binding of
Annexin V, time-lapse imaging, and TUNEL assay [2,3]. In
addition, evidance that NRIF3/DD1-mediated apoptosis in
breast cancer cells involves caspase-2 comes from studes
indicating that knockdown of caspase-2 expression transi-
ently by siRNA [2] or stably with shRNA [3] abrogates the
apoptotic response. Furthermore, zVAD-fmk did not block
the apoptotic response while apoptosis was blocked with
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caspase-2 in NRIF3/DD1-mediated apoptosis since zVAD-
fmk is not a target of caspase-2 while zVDVAD-fmk
exhibits a high affinity for caspase-2 [14]. Although
zVDVAD-fmk can target caspase-3, evidence that caspase-3
is not essential for the apoptotic response comes from the
finding that zVAD-fmk, which exhibits a high affinity for
caspase-3, does not block NRIF3/DD1-mediated apop-
tosis [2]. Furthermore, NRIF3/DD1 mediates apoptosis in
MCF-7 cells [2,5] which do not express caspase-3 [15,16].
To assess wether LNCaP cells undergo apoptosis by the
same pathway as breast cancer cells, we expressed GFP-
DD1 in LNCaP-AD, LNCaP-AI, and LNCaP-abl cells. Each
cell line exhibited apoptosis in response to GFP-DD1
(TUNEL assay) (Figure 1). Expression of GFP-DD1(S28A)
did not lead to apoptosis (not illustrated). In addition,
zVDVAD-fmk blocks apoptosis mediated by DD1 in the
prostate cancer cell lines (Figure 1). Like breast cancer cells
zVAD-fmk was without effect (not shown). These findings in
Figure 1 are identical to those found with a wide variety of
breast cancer cell lines [4,5] supporting the notion that the
prostate cancer cell lines undergo NRIF3/DD1 mediated
apoptosis through the same pathway. In addition, previous
studies indicated that caspase-2-dependent apoptosis re-
sulted from an increase in mitochondrial permeability [2,17].
Such signaling of caspase-2 to mitochondria is thought to
result from direct cleavage of the BH3-only protein BID
which functions with Bax to increase mitochondrial perme-
ability and release of factors that lead to apoptosis [17].
To further document that NRIF3/DD1-mediated apop-
tosis is associated with release of mitochondrial pro-
apoptotic factors in LNCaP cells, we examined the cell
distribution of AIF (Apoptosis Inducing Factor). AIF
normally localizes to the inside of the outer mitochon-
drial membrane [18]. With changes in mitochondrial
permeability AIF is released and localizes to the nucleus
where it initiates DNA fragmentation [18]. To examine
this we first transfected LNCaP-AI cells to express AIF-
GFP. Twenty-four h after expression of AIF-GFP, cells
were then transfected to express DD1 which leads to
apoptosis, or DD1(S28A) which is inactive [DD1 and DD1
(S28A) were expressed as GAL4 fusion proteins to ensure
nuclear localization]. Figure 2 illustrates the cell distribu-
tion of AIF-GFP in cells where DD1(S28A) was expressed.
AIF-GFP is localized completely outside of the nucleus
(nuclei are stained with DAPI). In contrast, cells which
express DD1 show complete nuclear localization of AIF-
GFP consistent with a DD1-mediated effect leading to
changes in mitochondrial permeability.
Conditional expression of DD1 and DD1(S28A) in LNCaP cells
To further study the mechanism of DD1-mediated apop-
tosis of LNCaP cells, we generated stable LNCaP-AI cell
lines expressing DD1-ERT2 or DD1(S28A)-ERT2. ERT2 isa mutated form of the human estrogen receptor-α ligand
binding domain that does not bind estrogen agonists but
binds the partial agonist–antagonist 4-hydroxytamoxifen
(4-OHT) [19]. Both DD1-ERT2 and DD1(S28A)-ERT2 are
expressed with an N-terminal nuclear localization signal
and a FLAG epitope to allow for estimation of expression
and cell distribution. Without 4-OHT, DD1-ERT2 and
DD1(S28A)-ERT2 are sequestered in a heat shock protein
complex mostly outside the nucleus. After 4-OHT incuba-
tion the chimeric proteins rapidly enter the nucleus. In
addition, 4-OHT stabilizes the chimeric protein further
increasing its level of expression in the cell. Such studies
in breast cancer cells indicate that after 4-OHT incubation
with DD1-ERT2 expressing cells, apoptosis (TUNEL) is
detected within 4 h and is maximal between 5–10 h [5].
No apoptosis was found with the breast cancer lines
expressing DD1(S28A)-ERT2 after 4-OHT incubation [5].
Figure 3A shows such a study in LNCaP-AI cells stably
expressing DD1-ERT2 or DD1(S28A)-ERT2. Eight h after
4-OHT incubation the DD1-ERT2 LNCaP-AI cells exhibit
extensive apoptosis by TUNEL assay while the DD1
(S28A)-ERT2 LNCaP-AI cells are TUNEL negative.
Role of FASTKD2 in Mediating Apoptosis by the NRIF3/DD1
Microarray studies with breast cancer cells expressing
DD1-ERT2 or DD1(S28A)-ERT2 incubated with or without
4-OHT identified the FASTKD2 gene as the pro-apoptotic
gene that is rapidly expressed when DIF-1 mediated repres-
sion is reversed by the binding of NRIF3/DD1 [5]. To
establish that DD1-mediated apoptosis in the DD1-ERT2
LNCaP-AI cells is mediated by FASTKD2, we first trans-
fected the cells with a control siRNA or an siRNA directed
against FASTKD2 mRNA. To obtain efficient knockdown
in LNCaP-AI cells, the cells were transfected with the siR-
NAs twice (on day 1 and day 2). Fifteen h after the second
transfection cells were incubated with 4-OHT for 15 h and
then examined for apoptosis by TUNEL assay (Figure 3B).
Cells treated with the FASTKD2 siRNA were TUNEL
negative while cells that received the control siRNA were
TUNEL positive. Thus, like breast cancer cells, DD1-
mediated apoptosis of LNCaP cells occurs through expres-
sion of the FASTKD2 gene.
FASTKD2 is an inner mitochondrial membrane protein
[13] and Figure 4A illustrates the domain organization of
FASTKD2. The protein contains an N-terminal mitochon-
drial uptake signal, two putative FAST kinase-like domains
(FAST1, FAST2) and a putative RNA-binding domain
(RAP) near the C-terminus [12]. To study expression of
the FASTKD2 gene, LNCaP-AI cells as well as HeLa cells
stably expressing DD1-ERT2 and DD1(S28A)-ERT2 were
incubated with 4-OHT or an EtOH vehicle control for 8 h
followed by analysis of FASTKD2 mRNA abundance by
quantitative qRT-PCR (Figure 4B). Prior to addition of
4-OHT, the cells received zVDVAD-fmk to block apoptosis
Figure 1 Expression of DD1 leads to apoptosis in androgen dependent and androgen independent LNCaP cell lines. LNCaP-AI, LNCaP-abl
and LNCaP-AD cells were transfected with 50 ng of GFP-DD1 using Lipofectamine 2000. Fifteen h later the cells were fixed and permeablized for
analysis of GFP fluorescence (green) or TUNEL assay (red). The Merged panel on the right also shows nuclei (blue) stained with DAPI. In the
bottom panels LNCaP-AI cells were treated with 20 uM zVDVAD-fmk prior to transfection with of GFP-DD1.
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found, FASTKD2 is not increased by DD1 in the two HeLa
cell lines (p = 0.73) [5]. However, FASTKD2 mRNA levels
were stimulated by 4-OHT in the DD1-ERT2 (p = 0.007)
but not in the DD1(S28A)-ERT2 LNCaP-AI cells (p = 0.32).
Based on sequence homology FASTKD2 is related to 4
other human proteins (FASTKD 1,3,4,5) [12]. All five pro-
teins localize to mitochondria and contain two putative
FAST kinase-like domains (FAST1, FAST2) and a putative
RNA-binding domain (RAP) near the C-terminus [12].
Although these proteins contain these FAST kinase-like
domains which are related to the originally identified
FASTK [20,21], they have not been documented to exhibit
kinase activity. In addition, the “kinase” domains do not
contain conserved sequences typical of a kinase ATP bind-
ing site. Furthermore, alignment of the FAST1_FAST2domains of FASTKD1-5 indicates that this region is about
20% similar/identical with a lot of gaps. Thus, it is not clear
that these proteins mediate their effects through changes
in phosphorylation. Although the biological functions of all
these FAST kinase domain containing factors is not fully
known, a recent study indicated that FASTKD3 influences
basal and stress induced mitochondrial oxygen consump-
tion [12]. To assess whether FASTKD genes other than
FASTKD2 are regulated by NRIF3/DD1, we used qRT-
PCR to study expression of all 5 FASTKD genes in both
LNCaP-AI cells and T-47D breast cancer cells stably
expressing DD1-ERT2. Figure 4C illustrates the results 8 h
after 4-OHT incubation. Only FASTKD2 mRNA levels are
increased in both DD1-ERT2 cell types (T-47D, p <0.001;
LNCaP, p = 0.005) while we consistently note a slight
reduction in FASTKD4 expression. A similar study with T-
Figure 3 Activation of DD1 leads to expression of FASTKD2 which mediates the apoptotic response. (A) LNCaP-AI cells stably expressing
DD1-ERT2 or DD1(S28A)-ERT2 were incubated with 1 uM 4-OHT for 8 h and then analyzed for DD1 and DD1(S28A) expression by immunofluorescense
using FLAG-M2 antibody (green) and apoptosis by TUNEL assay (red). Nuclei were stained with DAPI (blue). (B) LNCaP-AI cells stably expressing
DD1-ERT2 were transfected with a Control siRNA or an siRNA known to knock down expression of FASTKD2 [5]. Twenty-four h later the cells were
transfected again with the siRNAs as described in the Methods section. Twenty h after the second siRNA transfection cells were incubated with 4-OHT
for 15 h. Cells were then fixed and permeablized for TUNEL assay (red). Nuclei are stained with DAPI (blue). Cells treated with the FASTKD2 siRNA
exhibited essentially no apoptosis after 4-OHT incubation while cells treated with the Control siRNA showed extensive apoptosis.
Figure 2 DD1-mediated apoptosis in LNCaP cells leads to changes in mitochondrial membrane permeability and release of AIF which
translocates to the cell nucleus. LNCaP-AI cells were first transfected with a plasmid to express AIF-GFP. Twenty-four h later cells were
transfected to express DD1 which leads to apoptosis, or DD1(S28A) which is inactive [DD1 and DD1(S28A) were expressed as GAL4 fusion
proteins to ensure nuclear localization]. Fifteen h after the second transfection cells were fixed and permeablized for AIF-GFP fluorescence
(green). Nuclei were stained with DAPI (blue). The Figure shows an extra-nuclear mitochondrial distribution of AIF-GFP in cells expressing DD1
(S28A) while in cells expressing DD1, AIF-GFP is localized to the nucleus.
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Figure 4 FASTKD2 expression is enhanced by DD1 activation in LNCaP cells and is the only member of the FASTKD gene family that is
enhanced by DD1. (A) Domain structure of FASTKD2. (B) LNCaP-AI cells and HeLa cells stably expressing DD1-ERT2 or DD1(S28A)-ERT2 were first
incubated with 20 uM zVDVAD-fmk to block apoptosis and then treated with 4-OHT (1 uM) or EtOH vehicle for 8 h. FASTKD2 mRNA expression
was examined by qRT-PCR. Fold induction represents the FASTKD2 expression values of 4-OHT treated cells relative to those of EtOH treated cells.
Data represents the mean +/− SEM from three representative experiments and the p values are given in the text. (C) LNCaP-AI and T-47D breast
cancer cells stably expressing DD1-ERT2 were incubated with 4-OHT (1 uM) or EtOH vehicle for 8 h (cells were pretreated with 20 uM zVDVAD-fmk to
block apoptosis). The expression of the 5 FASTKD mRNAs (indicated as KD1, KD2, KD3, KD4, and KD5) was examined by qRT-PCR using the primers
indicated in the Methods section and in [12]. Fold induction represents the FASTKD expression values of 4-OHT treated cells relative to those of EtOH
treated cells. Data represents the mean +/− SEM from three representative experiments and the p values are given in the text.
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ERT2 showed no effect on any of the FASTKD mRNAs
(not shown).
Of the related FASTKD1-5 isoforms only FASTKD2
mediates apoptosis
To assess whether apoptosis mediated by FASTKD2 is
unique or is found with all the FASTKD proteins we
expressed all five FASTKD proteins as Yellow Fluorescent
Protein (YFP) chimeras. Similar to the original study with
these YFP chimeras [12] we found that all of the FASTKD
proteins localize to the peri-nuclear region (Figure 5)
which Simarro et al. have shown to be mitochondria [12].
However, when expressed in cells, only FASTKD2 leads to
apoptosis in HeLa, T-47D, and LNCaP cells. Shown in
Figure 5 is a representative study where apoptosis was
assessed by TUNEL assay in HeLa cells. Fifteen h after
expression of the FASTKD proteins, only cells expressing
FASTKD2 are TUNEL positive.
The FAST2 domain mediates the apoptotic effect of
FASTKD2
Although FASTKD2 is an inner mitochondrial membrane
protein, apoptosis mediated by FASTKD2 does not appear
to require mitochondrial localization since expression of
FASTKD2 lacking the N-terminal mitochondrial import
signal (ΔM-FASTKD2) leads to apoptosis [5]. This sug-
gests that when FASTKD2 is rapidly expressed, it acts to
activate pro-apoptotic or inhibit anti-apoptotic factors on
the surface or outside of mitochondria prior to import. To
assess the domain of FASTKD2 that mediates apoptosis
we generated vectors expressing the following regions ofFigure 5 Of the FASTKD isoforms only FASTKD2 mediates apoptosis.
chimeras with YFP at the C-terminus. Fifteen h later cells were fixed and pe
TUNEL assay (red). Nuclei were stained with DAPI (blue). The FASTKD-YFP c
documented to reflect mitochondrial localization [12]. Only expression of FFASTKD2; amino acids 1–455 which contains residues
N-terminal of the FAST kinase domains, amino acids
456–619 which contains the FAST1_FAST2 domains and
amino acids 538–619 which contains just the FAST2
domain [12] (see Figure 4A). FASTKD2 and FASTKD2
(1–455) are expressed with a C-terminal FLAG tag while
FASTKD2 (538–619) and FASTKD2 (456–619) were
expressed with GFP at their N-termini. Figure 6 shows a
representative study with these vectors in HeLa cells,
although similar results were found for T-47D and LNCaP
cells (not illustrated). Cells were transfected with the
above vectors and 15 h later analyzed for FLAG/GFP
expression and apoptosis by TUNEL assay. As previously
reported, full-length FASTKD2 exhibits a peri-nuclear
localization characteristic for mitochondria [12] and
mediates apoptosis. FASTKD2 (1–455) containing the N-
terminal mitochondrial import signal but lacking the
FAST1_FAST2 domains exhibits a similar cell distribution
as FASTKD2 but its expression did not lead to apoptosis.
GFP-FASTKD2(456–619) and GFP-FASTKD2(538–619)
are diffusely expressed in the cell and each resulted in
apoptosis indicating that it is the 81 amino acid FAST2
domain of FASTKD2 that initiates the apoptotic cascade.
Note that nearby cells not expressing GFP-FASTKD2
(456–619) or GFP-FASTKD2(538–619) (Figure 6) also
undergo apoptosis which is consistent with a bystander
effect we previously reported for NRIF3/DD1-mediated
apoptosis [5] which occurs through FASTKD2.
Discussion
FASTKD2 with a nonsense mutation in both alleles on
chromosome 2 was identified in a family with a transmittedHela cells were transfected to express the 5 FASTKD isoforms as YFP
rmeablized for analysis of YFP fluorescence (green) and apoptosis by
himeras localize in a peri-nuclear fashion which was previously
ASTKD2 leads to apoptosis.
Figure 6 The FAST2 domain mediates the apoptotic effect of FASTKD2. HeLa cells were transfected with 50 ng of vectors that express
either FASTKD2, FASTKD2(1–455) lacking the FASTKD2 FAST1_FAST2 and RAP domains, FASTKD2(456–619) which contains the FAST1_FAST2
domain or FASTKD2(538–619) which contains just the FAST2 domain. Fifteen h later cells were fixed and permeablized for TUNEL assay (red) and
fluorescence studies (green). Nuclei were stained with DAPI (blue). FASTKD2 and FASTKD2(1–455) were detected by immunofluorescence using
FLAG-M2 antibody while expression of the other FASTKD2 domains were detected as GFP chimeras.
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uals were shown to have a marked decrease in cytochrome
c oxidase activity (Complex IV), which receives electrons
from cytochrome c and transfers them to molecular oxygen
[13]. FASTKD2 localizes to the inner mitochondrial com-
partment and is thought to be a component of Complex IV
[13]. Fibroblasts from individuals with Infantile Mitochon-
drial Encephalophy show less apoptosis in response to
Staurosporine [13]. In microarray studies we previously
identified a rapid increase in expression of FASTKD2 in
breast cancer cells expressing NRIF3/DD1 but no change
in other cells types [5].
The FASTKD2 gene appears to be repressed by DIF-1
and the binding of NRIF3/DD1 leads to rapid de-repression
of the FASTKD2 gene [5]. Interestingly, the other members
of the FASTKD gene family are not enhanced through
the NRIF3/DD1/DIF-1 pathway in breast cancer cells
or LNCaP cells (Figure 4C) nor does their expression lead
to apoptosis (Figure 5). In other cell types examined the
FASTKD2 gene is not regulated by NRIF3/DD1 [5]. ChIP
analysis indicated that DIF-1, and its related associated
proteins IRF2BP1 and EAP-1, bind to the first untrans-
lated exon of the FASTKD2 gene in breast cancer cells
while DIF-1 does not bind to the gene in HeLa cells [5].
Since FASTKD2 is a highly pro-apoptotic factor, its
expression and activity must be tightly controlled and
regulated. Mitochondrial proteins encoded by nucleargenes are synthesized on free ribosomes and are thought
to enter mitochondria directly through a pre-sequence;
while other proteins with internal targeting signals associ-
ate with chaperones which target the mitochondrial
import mechanism [22]. The mechanism of FASTKD2
mitochondrial import is not known but it does contain an
N-terminal mitochondrial import signal which when re-
moved prevents mitochondrial import [5,13]. If FASTKD2
is directly imported via its pre-sequence, its expression
needs be under tight control since over-expression can
lead to apoptosis since mitochondrial import of certain
proteins may not be an extremely rapid process [22]. In
our studies, expression of NRIF3/DD1 leads to a rapid
3- to 7-fold increase in FASTKD2 expression within 5–8 h
in breast cancer cell lines [5] as well as in LNCaP cells
(Figure 4B and 4C). This rapid increase in FASTKD2 may
not be rapidly imported into mitochondria and, thus, gener-
ate an extra-mitochondrial “threshold” level that is sufficient
to spuriously initiate an apoptotic response. Consistent with
that model is that expression of FASTKD2 without the
mitochondrial import signal [5], or the FAST1_FAST2
region or just the FAST2 domain (Figure 6), which do not
localize to mitochondria, leads to rapid apoptosis. Thus, the
81 amino acid FAST2 region mediates the pro-apoptotic
effect of FASTKD2. As indicated in the results section, the
FAST1_FAST2 domains do not contain conserved motifs
typical of a kinase and the FAST1_FAST2 domains of the
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with significant gaps. Although we can’t exclude the
possibility that FASTKD2 mediates its apoptotic response
through phosphorylation, it is likely that it initiates apop-
tosis via a different mechanism.
Why NRIF3/DD1 regulates the FASTKD2 gene in breast
cancer cells and LNCaP cells but not other cell types is
currently unknown. For breast cancer cells we showed that
the DIF-1 complex containing the related proteins IRF-
2BP1 and EAP-1 binds to the 5’-untranslated exon of the
FASTKD2 gene [5]. However, the DIF-1 complex does not
bind to this region of the FASTKD2 gene in HeLa cells
which expresses DIF-1, IRF2BP1 and EAP1 at similar
levels as in breast cancer cells [5]. Mass spectrometry and
silver stain gel studies indicate that the proteins associated
with the DIF-1 complex differ in HeLa and T-47D breast
cancer cells [5]. Thus, cells where FASTKD2 is regulated
by DIF-1 may express components that allow for DIF-1
complex binding to the gene, possibly displacing regula-
tory factors that act to regulate low levels of expression of
the gene in other cell types. Alternatively, cells where DIF-
1 does not regulate the FASTKD2 gene, such as HeLa
cells, may contain factors that interact with the DIF-1
complex preventing the complex from binding to and
regulating the gene. In future mass spectrometry and
functional studies we hope to explore such possible
alternative models as well as identify the cellular target(s)
of the FAST2 domain.
Conclusions
The NRIF3/DD1/DIF-1/FASTKD2 pathway is a new
pathway to therapeutically target Estrogen Receptor
negative breast or androgen independent prostate cancer
or metastatic cancer for therapy. In particular, in this
study we found that expression of NRIF3/DD1 efficiently
leads to apoptosis in LNCaP-AI and LNCaP-abl cells
which are much more resistant to apoptosis than the
parent LNCaP-AD cells [10,11]. In previous studies we
found that the 104 C-terminal amino acids of DIF-1
binds NRIF3/DD1 [4]. Future structural studies with this
region of DIF-1 with a DD1-S28-phosphopeptide will
hopefully lead to a crystal structure that provides a picture
of the pharmacophore or chemical blueprint of the
DD1/DIF-1 interaction. This can provide the structural
basis for identifying small molecule DD1 mimetics that
would be useful in targeting DIF-1 in breast and prostate
cancer in animal models and in future clinical trials.
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